ArticleDrug design, development and therapy2014
Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis.
Article in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.Drug design, development and therapy · 2015Pooled it
- Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.Drug design, development and therapy · 2015Pooled it
- Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis.Drug design, development and therapy · 2015Pooled it
- Fasudil Attenuates Concanavalin A-Induced Autoimmune Hepatitis and Is Associated with Suppression of RhoA/ROCK and TLR4/NF-κB Signaling and Modulation of Immune Responses.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Enhancing Liver Delivery of Gold Nanoclusters via Human Serum Albumin Encapsulation for Autoimmune Hepatitis Alleviation.Pharmaceutics · 2024Article
- Article
- Daidzein ameliorated concanavalin A-induced liver injury through the Akt/GSK-3β/Nrf2 pathway in mice.Annals of translational medicine · 2021Article
- Huganbuzure Granule Attenuates Concanavalin-A-Induced Immune Liver Injury in Mice via Regulating the Balance of Th1/Th2/Th17/Treg Cells and Inhibiting Apoptosis.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Hydrogen sulfide and hepatic lipid metabolism - a critical pairing for liver health.British journal of pharmacology · 2020Review
- Human liver stem cells attenuate concanavalin A-induced acute liver injury by modulating myeloid-derived suppressor cells and CD4Stem cell research & therapy · 2019Article
- Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease.Oxidative medicine and cellular longevity · 2019Review
- 15-Deoxy-ΔActa pharmacologica Sinica · 2017Article
- The protective effects of shikonin on hepatic ischemia/reperfusion injury are mediated by the activation of the PI3K/Akt pathway.Scientific reports · 2017Article
- Functional and Molecular Insights of Hydrogen Sulfide Signaling and Protein Sulfhydration.Journal of molecular biology · 2017Review
- Hydrogen-Rich Saline Alleviates Kidney Fibrosis Following AKI and Retains Klotho Expression.Frontiers in pharmacology · 2017Article
- Review
- Shikonin Attenuates Concanavalin A-Induced Acute Liver Injury in Mice via Inhibition of the JNK Pathway.Mediators of inflammation · 2016Article
- Hydrogen-Rich Saline Promotes the Recovery of Renal Function after Ischemia/Reperfusion Injury in Rats via Anti-apoptosis and Anti-inflammation.Frontiers in pharmacology · 2016Article
- Article
- Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis via the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagy.Drug design, development and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydrogen sulfide (H2S) is known to exert anti-inflammatory properties. Apoptosis and autophagy play important roles in concanavalin A (Con A)-induced acute hepatitis. The purpose of this study was to explore both the effect and mechanism of H2S on Con A-induced acute hepatitis.
methodsBALB/c mice were randomized into sham group, Con A-injection group, and 14 μmol/kg of sodium hydrosulfide (NaHS, an H2S donor) pretreatment group.
resultsAspartate aminotransferase, alanine aminotransferase, and pathological damage were significantly ameliorated by NaHS pretreatment. NaHS pretreatment significantly reduced the levels of interleukin-6 and tumor necrosis factor-α compared with those of the Con A group. The expression of Bcl-2, Bax, Beclin-1, and LC3-2, which play important roles in the apoptosis and autophagy pathways, were also clearly affected by NaHS. Furthermore, NaHS affected the p-mTOR and p-AKT.
conclusionH2S attenuates Con A-induced acute hepatitis by inhibiting apoptosis and autophagy, in part, through activation of the PtdIns3K-AKT1 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.